Inotiv's low P/S ratio may be due to investor worries about its future growth. The company's below-industry growth forecast could be causing shareholder unease, leading to a lower P/S ratio. A significant turnaround would be needed for the P/S ratio to increase.
Inotiv's P/S ratio lags behind peers despite upward share trends and high revenue growth, indicating potential lack of investor confidence in future growth. Unseen threats might be lowering the P/S ratio, risking near term underperformance.
Analysts are divided on Inotiv's future following varying price target predictions. Despite the expectation of increased losses next year, revenue estimates are steady. However, Inotiv's revenue growth is anticipated to decelerate, underperforming the broader industry.
QUICK SCALP 2 $NOTV - STOCK & OPTION PLAY ALERT ON: $7.05 ON THE WATCH: $7.18 🥇 SIGNED OF MORE UPTREND: $7.33 NEED IT TO BREAK OVER: $7.44 key indicator for MORE uptrend $7.56 confirmation uptrend - $7.63 mini breakout - $7.74.$Inotiv(NOTV.US)$
Inotiv股票討論區
Daily alerts recap 🔥 150%+
Current watch ⚡️
TOP WATCH AH + 7/21 ⚡️⚡️
突破站穩6.39,就高看8.5
錢途無量
ALERT ON: $7.05
ON THE WATCH: $7.18
🥇 SIGNED OF MORE UPTREND: $7.33
NEED IT TO BREAK OVER: $7.44
key indicator for MORE uptrend $7.56
confirmation uptrend - $7.63
mini breakout - $7.74. $Inotiv(NOTV.US)$
💵
Stocks
APVO ⭐️⭐️⭐️ very good 5.49 to 7s 30%+
NOTV ⭐️⭐️ 4.21 ran to 4.70s 15%+
AMAM ⭐️⭐️ 2.79 ran to 3.40s 15%+
AFMD ⭐️⭐️⭐️1.22 zone ran to 1.40s 15%+
Options
CVX ⭐️⭐️ 2.64 to 2.90s 10%+ (potential hold)
TSLA ok to 1st-2nd target
Addition
COP to 112s am from Friday 20%
$Aptevo Therapeutics(APVO.US)$$Inotiv(NOTV.US)$$Ambrx Biopharma(AMAM.US)$$Affimed NV(AFMD.US)$$雪佛龍(CVX.US)$$特斯拉(TSLA.US)$$康菲石油(COP.US)$
暫無評論